FOLH1 and neoplasm: Because of the increasing interest in using [177Lu]Lu-PSMA ligands in early disease stages (e.g. PSMAfore and PSMAddition trials), especially the tumor-to-kidney ratio is one of the most important selection criteria for novel radioligands in order to reduce potential renal side effects in men with several years of life expectancy.